Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Amandine, Savry"'
Autor:
Amandine Savry, Manon Carre, Raphael Berges, Amandine Rovini, Isabelle Pobel, Christine Chacon, Diane Braguer, Véronique Bourgarel-Rey
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 1, Pp 49-60 (2013)
Bcl-2 is commonly overexpressed in tumors, where it is often associated with unfavorable outcome. However, it has also been linked to a favorable sensitivity to microtubule-targeting agents (MTAs). We show that Bcl-2– overexpressing lung and breast
Externí odkaz:
https://doaj.org/article/6afa7a48fb074511bf561ba859ff26c3
Autor:
Florian Correard, Laurence Gauthier-Villano, Amandine Savry, Bertrand Pourroy, Pascale Pisano
Publikováno v:
American Journal of Health-System Pharmacy
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
American Journal of Health-System Pharmacy, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
American Journal of Health-System Pharmacy, 2014, 71 (15), pp.1288-1291. ⟨10.2146/ajhp130700⟩
Purpose The visual compatibility of a solution of defibrotide (the only drug recommended for treatment and prophylaxis of hepatic venoocclusive disease) with solutions of various drugs commonly administered in bone marrow transplant procedures was st
Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?
Autor:
Bertrand Pourroy, Amandine Savry, Pascale Pisano, Magali Rocca, Laurence Gauthier-Villano, Youssef Bennis
Publikováno v:
International Journal of Clinical Pharmacy. 36:420-429
Background Nephrotoxicity is the dose-limiting side effect of cisplatin justifying the assessment of renal function for dose adjustment. Objective To determine whether appropriate dose adjustment is made in patients with renal impairment using the Co
Autor:
Diane Braguer, Véronique Bourgarel-Rey, Manon Carré, Amandine Savry, Raphael Berges, Christine Chacon, Amandine Rovini, Isabelle Pobel
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 1, Pp 49-60 (2013)
Bcl-2 is commonly overexpressed in tumors, where it is often associated with unfavorable outcome. However, it has also been linked to a favorable sensitivity to microtubule-targeting agents (MTAs). We show that Bcl-2– overexpressing lung and breast
Autor:
Amaury, Guédon, Angélique, Rome, Jean-Laurent, Deville, Michael, Besse, Ludivine, Blanchet, Amandine, Savry, Laurence, Gauthier-Villano, Pierre, Bertault-Peres, Bertrand, Pourroy
Publikováno v:
American journal of medical quality : the official journal of the American College of Medical Quality. 32(2)
Autor:
Philippe, Garrigue, Marc, Montana, Christophe, Ventre, Amandine, Savry, Laurence, Gauthier-Villano, Pascale, Pisano, Bertrand, Pourroy
Publikováno v:
International journal of pharmaceutical compounding. 20(2)
Closed-system transfer devices enhance the drug handlers' protection against hazardous drugs exposure by prohibiting the escape of liquid or vapor from the system. PhaSeal (Becton Dickinson), a reference closed-system transfer device, includes a vial
Autor:
Jean Imbert, Céline Bressin, Diane Braguer, Amandine Savry, Véronique Bourgarel-Rey, Christine Chacon, Yves Barra, Guoqiang Hua, Manon Carré
Publikováno v:
Biochemical Pharmacology
Biochemical Pharmacology, Elsevier, 2009, 78 (9), pp.1148. ⟨10.1016/j.bcp.2009.06.025⟩
Biochemical Pharmacology, Elsevier, 2009, 78 (9), pp.1148. ⟨10.1016/j.bcp.2009.06.025⟩
International audience; The Bcl-2 family contains a panel of proteins which are conserved regulators of apoptosis in mammalian cells, like the anti-apoptotic protein Bcl-2. According to its significant role in altering susceptibility to apoptosis, th
Autor:
Bertrand Pourroy, Youssef Bennis, Florian Correard, Amandine Savry, Christophe Sauzet, Pascale Pisano, Laurence Gauthier-Villano, Marc Montana
Publikováno v:
International Journal of Pharmaceutics
International Journal of Pharmaceutics, Elsevier, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
International Journal of Pharmaceutics, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
International Journal of Pharmaceutics, Elsevier, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
International Journal of Pharmaceutics, 2015, 495 (2), pp.956-962. ⟨10.1016/j.ijpharm.2015.10.012⟩
Introduction Epirubicin is widely used for conventional transcatheter arterial chemoembolization (cTACE) in patients with hepatocellular-carcinoma. However, there is no data about its stability in solution at concentration higher than 2 mg/L, yet nee
Autor:
Florian Correard, Bertrand Pourroy, Pascale Pisano, Amandine Savry, Laurence Gauthier Villano, Fabien Espitallier
Publikováno v:
American Journal of Health-System Pharmacy
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
American Journal of Health-System Pharmacy, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
American Journal of Health-System Pharmacy, 2016, 73 (11), pp.748-750. ⟨10.2146/ajhp140625⟩
Decitabine is indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukemia in adults age 65 years or older who are not candidates for standard induction chemotherapy.[1][1] The decitabine powder must be aseptically recon
Autor:
Bertrand Pourroy, Laurence Gauthier Villano, Florian Correard, Pascale Pisano, Amandine Savry
Publikováno v:
American Journal of Health-System Pharmacy
American Journal of Health-System Pharmacy, 2014, 71 (3), pp.180-181. ⟨10.2146/ajhp130586⟩
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2014, 71 (3), pp.180-181. ⟨10.2146/ajhp130586⟩
American Journal of Health-System Pharmacy, 2014, 71 (3), pp.180-181. ⟨10.2146/ajhp130586⟩
American Journal of Health-System Pharmacy, American Society of Health-System Pharmacists, 2014, 71 (3), pp.180-181. ⟨10.2146/ajhp130586⟩
Azacitidine is labeled in the United States for the treatment of myelodysplastic syndrome.[1][1] The manufacturer indicates a reduction in stability if the diluent used to reconstitute the lyophilized azacitidine powder is warmer than 8 °C. In fact,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b79b5dc6f3633655a683f5cde86712a8
https://hal.science/hal-01773013
https://hal.science/hal-01773013